E Fund Management Co., Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
E Fund Management Co., Ltd.
- $1.6 Billion
- Q1 2024
A detailed history of E Fund Management Co., Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 10,248 shares of CRNX stock, worth $449,169. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,248
Previous 13,069
21.59%
Holding current value
$449,169
Previous $464,000
3.23%
% of portfolio
0.03%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
221Shares Held
75.8MCall Options Held
631KPut Options Held
749K-
Black Rock Inc. New York, NY5.44MShares$238 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.23MShares$229 Million2.68% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.95MShares$217 Million0.59% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.16MShares$182 Million5.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$168 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.36B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...